Previous 10 | Next 10 |
Mersana Therapeutics (MRSN) gaining 5.7% after activist Sarissa Capital disclosed a 5.5% stake in a 13G filing, up from an earlier stake of 4.1%.The increased stake is interesting in that Mersana CEO is familiar to Sarissa as the fund targeted Ariad Pharma and Bioverativ, wher...
CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announce...
On 8 January, Bain Capital's Life Sciences Fund II (BCLS II) purchased 89,143 shares in Mersana Therapeutics ([[MRSN]] +3.3%) at a weighted average purchase price of $18.4/share in open market transactions. Additionally, during this week, BCLS II bought 66,857 shares and 66,857 sha...
Mersana Therapeutics is a clinical-stage biopharmaceutical company developing antibody-drug conjugates ("ADCs") for cancer patients. Mersana has developed an early-stage pipeline of 8 therapeutic programs with 2 clinical-stage therapeutics in phase 1 (XMT-1536, -1592) expected to prog...
This article reviews the Value & Momentum Breakouts 2020 trading year and addresses new strategies, models, and enhancements for 2021. 10 different model portfolios beat the S&P 500 in 2020 and six of these methods have beaten the S&P 500 consistently the past several year...
CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced...
Shares of Mersana Therapeutics (NASDAQ: MRSN) were crashing 29.1% lower as of 12:47 p.m. EST on Tuesday. The steep decline came after the biotech provided a corporate and pipeline update earlier in the day. Investors were especially disappointed with new data from an early-stage cli...
Gainers: Synthetic Biologics (SYN) +141%.Helius Medical Technologies (HSDT) +91%.The Peck Company (PECK) +79%.Atomera (ATOM) +50%.Check-Cap (CHEK) +49%.Naked Brand Group (NAKD) +42%.The9 (NCTY) +37%.Gritstone Oncology (GRTS) +36%.Boston Private Financial (BPFH) +31%.Jaguar Heal...
Mersana Therapeutics tanks ([[MRSN]] -23.4%) apparently on updated data from the expanded cohort of Phase 1 trial evaluating its XMT-1536 treatment, where it showed a 28% objective response rate in ovarian cancer, down from 35% during its preliminary analysis in May last year.31% of...
Gainers: Synthetic Biologics (SYN) +149%, Check-Cap (CHEK) +59%, Jaguar Health (JAGX) +50%, Cyclo Therapeutics CYTH +36%, Zomedica (ZOM) +42%.Losers: Bionano Genomics BNGO -29%, Mersana Therapeutics (MRSN) -23%, Millendo Therapeutics...
News, Short Squeeze, Breakout and More Instantly...
Mersana Therapeutics Inc. Company Name:
MRSN Stock Symbol:
NASDAQ Market:
Mersana Therapeutics Inc. Website:
Maximum tolerated dose not yet established in Phase 1 clinical trial of XMT-1660; enrollment in dose escalation and backfill cohorts continuing in parallel; expect to announce initial clinical data and initiate expansion in the second half of 2024 Patient recruitment ongoing in Phase 1 cl...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that ...
2024-03-18 08:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...